Efficacy of montelukast sodium combined with vitamin D in treatment of wheezing in infants and changes of lung function and cytokines / 实用医学杂志

ABSTRACT

Objective To explore the clinical efficacy of Montelukast Sodium combined with vitamin D in the treatment of infant wheezing, and to detect the expression level of P13K, NF-kappa B and STAT1 in peripheral blood mononuclear cells (PBMC) in infants, and to explore its significance. Methods A total of 640 children diagnosed as infant wheezing from January 2016 to June 2018 were selected as the research subjects and 160 cases of infants with wheezing remission were divided into control group with 80 cases given Montelukast Sodium Chewable Tablets 4 mg/d, and treatment group with 80 cases additionally taken vitamin D 0.25 g/d for 12 weeks. The changes of pulmonary function in infants and the levels of ALP, 25- (OH) D3 and IgA were compared before and after the treatment. The levels of P13K, NF-κB and ST AT1 mRNA and protein in peripheral blood mononuclear cells were detected by RTqPCR and Western blot respectively. Results The RR in the infantile asthmatic stage of attack was significantly faster than that in the control group, while the VT/kg, TPTEF/TE and VPEF/VE in the onset period in the treatment group were also lower than those in the control group and the difference was significant (P < 0.05). There were significant differences in cough/wheezing, wheezing, cough and basic values after treatment for 4 and 12 weeks in the treatment group (P< 0.05). Compared with those in the control group and before the treatment, the levels of ALP, 25- (OH) D3 and IgA in the treatment group increased significantly after the treatment (P < 0.05). The expression levels of P13 K, NF-κB and STAT1 mRNA and protein in PBMC of the treatment group were significantly lower than those before the treatment (P < 0.05). After 12 weeks of treatment, the PTEF (mL/s) , TPTEF/TE, and VPEF/VE in the treatment group were significantly higher than those before the treatment (P < 0.05). Conclusion The combination of Montelukast Sodium and vitamin D in the treatment of infants with asthmatic disease can significantly alleviate the symptoms and signs of children, and also significantly improve the related laboratory indicators.